Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation

Haematologica

Volumn 84, Issue 1, 1999, Pages 71-79

  Stocchi, Raffaella ^a   Ward, Kate N ^b   Fanin, Renato ^a   Baccarani, Michele ^a   Apperley, Jane F ^b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Allogeneic BMT; CMV infection and disease

Indexed keywords

ACICLOVIR; CD8 ANTIGEN; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; PLACEBO; VIRUS DNA;

ADOPTIVE TRANSFER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DONOR; HIGH RISK PATIENT; HUMAN; IMMUNOPROPHYLAXIS; INTRAVENOUS DRUG ADMINISTRATION; MORBIDITY; MORTALITY; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS PNEUMONIA;

EID: 0032880172     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990; 12:suppl.7:S701-10.
2. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991; 72:2059-64.
3. Minton EJ, Tysoe C, Sinclair JH, Sissons JC. Human cytomegalovirus infection of the monocytes/macrophages lineage in bone marrow. J Virol 1994; 68:4017-21.
4. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91:119-26.
5. Mindelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol 1996; 77:3099-102.
6. Michelson S. Interaction of human CMV with monocytes/macrophages: a love-hate relationship. Pathol Biol Paris 1997; 45:146-58.
7. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153:478-88.
8. Miller W, Flynn P, Mc Cullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft versus host disease. Blood 1986; 67:1162-7.
9. Wingard JR, Chen DY, Burns WH, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71:1432-7.
10. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viraemia. J Infect Dis 1990; 162:373-80.
11. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review often years experience. Rev Infect Dis 1982; 4:1119-32.
12. Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation.Transplantation 1993; 55:1339-46.
13. Meyers JD, Spencer HC Jr, Watts JC, et at. Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med 1975; 82:181-8.
14. Beschorner WE, Hutchins GM, Burns WH, Saral R, Tutschka JA, Santos GW. Cytomegalovirus pneumonia in bone marrow transplant recipients: miliary and diffuse patterns. Am Rev Respir Dis 1980; 122:107-14.
15. McDonald GB, Sharma P, Hackman RC, Meyers JD, Thomas ED. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 1985; 88:1111-7.
16. Spencer GD, Hackman RC, McDonald GB, et al. A prospective study of unexplained nausea and vomiting after marrow transplantation. Transplantation 1986; 42:602-7.
17. Wingard JR, Piantadosi S, Burns WH, Zahurak ML, Santos GW, Saral R. Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Rev Infect Dis 1990; 12:S793-804.
18. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118:179-84.
19. Prentice HG, Gluckman E, Powles RL, et al. For the European Acyclovir for CMV prophylaxis Study Group. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343:749-53.
20. Aschan J, Ringden O, Ljungman P, Lonnqvist B, Ohlman S. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand J Infect Dis 1992;24:143-50.
21. Verdonck LF, van Heugten H, de Gast GC. Delay in platelet recovery after bone marrow transplantation: impact of cytomegalovirus infection. Blood 1985; 66:921-5.
22. Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19:287-98.
23. Hersman J, Meyers JD, Thomas ED, Buckner CD, Clift R. The effect of granulocyte transfusion on the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med 1982; 96: 149-52.
24. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314:1006-10.
25. Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 1990; 12 (Suppl. 7):S776-92.
26. Marks DI, Culis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using siblings and volunteer unrelated donors. Ann Intern Med 1993; 119:207-14.
27. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddel SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-9.
28. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330:827-38.
29. Speck B, Zwaan FE, Rood JJ, Eernisse JG. Allogeneic bone marrow transplantation in a patient with aplastic anaemia using a phenotypically HLA-identical unrelated donor. Transplantation 1973; 16:24-8.
30. Hansen JA, Clift RA, Thomas ED, Buckner CD, Storb R, Giblett ER. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980; 303:565-7.
31. Hows JM, Yin JL, Marsh J, et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anaemia and leukemia. Blood 1986; 68: 1322-8.
32. Hows J, Bradley BA, Gore S, Downie T, Howard M, Gluckman E on behalf of the International Marrow Unrelated Search and Transplant (IMUST) Study: Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12:371-80.
33. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995;86:3979-86.
34. Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. Bone Marrow Transplant 1997; 19:241-8.
35. Ward KN, Roberts IAG, van Rhee F. Ganciclovir and the prevention of CMV disease after allogeneic BMT: policy at the Hammersmith Hospital. Bone Marrow Transplant 1994; 13:230-1.
36. Meyers JD, Flournoy N, Thomas ED. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis 1980; 142:816-24.
37. Quinnan GU, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLA restricted T lymphocyte and non T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med 1982; 307:7-13.
38. Ljungman P, Lonnqvist B, Wahren B, et al. Lymphocyte responses after cytomegalovirus infection in bone marrow transplant recipients: a 1 year follow-up. Transplantation 1985; 40:515-20.
39. Reusser P, Riddell S, Meyers J, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78:1373-80.
40. Quinnan GV, Kirmani N, Rook AH, et al. HLA-restricted T lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Eng J Med 1982; 307:7-13.
41. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 1992; 257:238-41.
42. Riddell SR, Greenberg PD. Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. Curr Top Microbiol Immunol 1994; 189:9-34.
43. Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19:1111-6.
44. Ljungman P, Aschan J, Azinge JN, et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors disease after allogeneic marrow transplantation. Br J Hematol 1993: 83:118-24.
45. Heagy W, Crumpacker C, Lopez PA, Finberg RA. Inhibition of immune functions by antiviral drugs. J Clin Invest 1991; 87:1916-23.
46. Tocci MJ, Livelli TJ, Perry HC, Crumpacker CS, Field AK. Effect of nucleoside analog 2′-nor-2′-deoxyguanosine on human cytomegalovirus replication. Antimicrob Ag Chem 1983; 25:247-55.
47. Riddell S R, Rabin M, Geballe AP, Britt WJ, Greenberg PD. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991; 146:2795-800.
48. Winston DJ, Gale RP. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplant 1991; 8:7-11.
49. Weiner RS, Bortin MM, Gale RP, et al. Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 1986; 104:168-75.
50. Cheung KS, Lang DJ. Transmission and activation of cytomegalovirus with blood transfusion: a mouse model. J Infect Dis 1977; 135:841-5.
51. Braun RW, Reiser HC. Replication of human cytomegalovirus in human peripheral blood T cells. J Virol 1986; 60:29-36.
52. Klein HG. Wolf in wolf's clothing: is it time to raise the bounty on the passenger leukocyte? Blood 1992; 80:1865-8.
53. Martin PJ. Increased disparity for minor histocompatibility antigens as a potential cause of increased GvHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant. 1991; 8:217-23.
54. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of nematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81:249-53.
55. Petersdorf EW, Smith AG, Mickelson EM, et al. The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. Blood 1993; 81:1923-32.
56. Wade JC, Hintz M, McGuffin RW, Springmeyer SC, Connor JD, Meyers JD. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med 1982; 73:249-56.
57. Tyms AS, Davis JM, Jeffries DJ, Meyers JD. BWB759U, an analogue of acyclovir, inhibits human cytomegalovirus in vitro. Lancet 1984; 2:924-5.
58. Shepp DH, Dandliker PS, de Miranda P, et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985; 103:368-73.
59. Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplant. Ann Intern Med 1988; 109:783-8.
60. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with a combination of ganciclovir and high dose intravenous immunoglobulin. Ann Intern Med 1988; 109:777-82.
61. Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human CMV-associated interstitial pneumonitis in bone marrow allograft recipients. Transplantation 1988; 46:905-7.
62. Helgstrand E, Eriksson B, Johansson NG, et al. Trisodium phosphonoformate, a new antiviral compound. Science 1978; 201:819-21.
63. Reno JM, Lee LF, Boezi JA. Inhibition of herpesvirus replication and herpesvirus-induced deoxyribonucleic acid polymerase by phosphonoformate. Antimicrob Agents Chemother 1978; 13:188-92.
64. Apperley JF, Marcus RE, Goldman JM, Wardle DG, Gravett PJ, Chanas A. Foscarnet for cytomegalovirus pneumonitis [letter]. Lancet 1985; May 18:1151.
65. Ringden O, Wilczek H, Lonnqvist B, Gahrton G, Wahren B, Lernestedt JO. Foscarnet for cytomegalovirus infections [letter]. Lancet 1985; June 29:1503-4.
66. Akesson-Johansson A, Lernestedt JO, Ringden O, Lonnqvist B, Wahren B. Sensitivity of cytomegalovirus to intravenous foscarnet treatment. Bone Marrow Transplant 1986;1:215-20.
67. Ringden O, Lonnqvist B, Paulin T, et al. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother 1986; 17:373-87.
68. Drobyski WR, Knox K, Carrigan DR, Ash RC. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation 1991; 52: 155-7.
69. Bacigalupo A, Bregante S, Tedone E, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 1996; 62:376-80.
70. Boivin G, Chan S, Querk MR, Erice A, Jordan MC. Detection of ganciclovir resistance mutations quantification of cytomegalovirus DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996; 173:523-8.
71. Lipson SM, Soni M, Biondo FX, Shepp DH, Kaplan MH, Sun T. Antiviral susceptibility testing-flow cytometric analysis (AST-FCA) for the detection of CMV drug resistance. Diagn Microbiol Infect Dis 1997; 28: 123-9.
72. Griffiths PD, Stirk PR, Ganczakowski M, et al. Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci. Lancet 1984; ii:1242-4.
73. van Der Bij W, Torensma R, Van Son JW, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988; 25:179-88.
74. van der Bij W, Schirm J, Torensma R, van Son WJ, Tegzess AM, de The TH. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988; 26:2531-5.
75. Jiwa NM, van Gemert GW, Rapp AK, et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viraemic transplant recipients by polymerase chain reaction. Transplantation 1989; 48:72-6.
76. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86:2815-20.
77. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325:1601-7.
78. de The' TH, van der Ploeg M, van der Berg AP, et al. Direct detection of cytomegalovirus in peripheral blood leukocytes: a review of the antigenemia assay and polymerase chain reaction. Transplantation 1992; 54:193-8.
79. Vlieger AM, Boland GJ, Jiwa NM, et al. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplant 1992; 9: 247-53.
80. Boeckh M, Bowden RA, Goodrich JM, et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic bone marrow transplantation. Blood 1992; 80:1358-64.
81. Gondo H, Minematsu T, Harada M, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994, 86:130-7.
82. de The' TH, van der Bij W, van der Berg AP, et al. Cytomegalovirus antigenemia. Rev Infect Dis 1990; 12(Suppl.7):S737-44.
83. Revello MG, Percivalle E, Zavattoni M, et al. Detection of human cytomegalovirus immediate-early antigen in leukocytes as a marker of viremia in immunocompromised patients. J Med Virol 1989; 29:88-93.
84. Schmidt CA, Oettle H, Wilborn F, et al. Demonstration of cytomegalovirus after bone marrow transplantation by polymerase chain reaction, virus culture and antigen detection in buffy coat leukocytes. Bone Marrow Transplant 1994; 13:71-5.
85. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the Polymerase Chain Reaction technique. Blood 1991; 77:1104-10.
86. Hebart H, Muller C, Loffler J, Jahn G, Einsele H. Monitoring of cytomegalovirus infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant 1996; 17: 861-8.
87. Goto H, Yuasa K, Sakamaki H, et al. Rapid detection of CMV pneumonia in recipients of bone marrow transplant: evaluation and comparison of 5 survey methods for bronchoalveolar lavage fluid. Bone Marrow Transplant 1996; 17:855-60.
88. Stanier P, Taylor DL, Kitchen AD, Wales N, Tryhorn Y, Tyms AS. Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors. Br Med J 1989; 299:897-8.
89. Gerna G, Furione M, Baldanti F, Percivalle E, Comoli P, Locatelli F. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. B J Haematol 1995; 91:674-83.
90. Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant 1994; 13:499-510.
91. Miller WJ, McCullough J, Balfour HH, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomised trial of blood product screening. Bone Marrow Transplantation 1991; 7: 227-34.
92. Bowden RA, Slichter SJ, Savers MH, et al. A comparison of filtered leukocytes-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplantation. Blood 1995; 86:3598-603.
93. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318:70-5.
94. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman Sj, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant. N Engl J Med 1991; 324:1005-11.
95. Atkinson K, Downs K, Golenia M, et. al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br J Haematol 1991; 79: 57-62.
96. Yau J, Dimopoulos MA, Huan SD, et al. Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. Eur J Haematol 1991; 47:371-6.
97. von Bueltingsloewen A, Bordigoni P, Witz F, et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1991; 325:1601-7.
98. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118:173-8.
99. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88:4063-71.
100. Ringden O, Lonnqvist B, Aschan J, Sundberg B. Foscarnet prophylaxis in marrow transplant recipients [Letter]. Bone Marrow Transplant 1989; 4:713.
101. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166:473-9.
102. Lonnqvist B, Aschan J, Ringden O. Foscarnet as inpatient prophylaxis only is insufficient to prevent cytomegalovirus infection after marrow transplantation. J Infect Dis 1993; 168:1073.
103. Bacigalupo A, Tedone E, Van Lint MT, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13:783-8.
104. Ippoliti C, Morgan A, Warkentin D, et al. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant 1997; 20:491-5.
105. Ljungman P, Oberg G, Aschan J, et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 18:5665-8.
106. Atkinson K, Arthur C, Bradstock K, et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune suppressed HLA-identical unrelated donor marrow transplant recipients. Bone Marrow Transplant 1995; 16:401-5.
107. Stocchi R, Szydlo R, Craddock C, et al. A comparison of prophylactic versus pre-emptive ganciclovir to prevent cytomegalovirus disease after volunteer unrelated donor bone marrow transplant. Bone Marrow Transplant 1998; in press.
108. Locatelli F, Percivalle E, Comoli P, et al. Human cytomegalovirus infection in pediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment of HCMV antigenemia on patient's outcome. Br J Haematol 1994; 88:64-71.
109. Onbluetzingsloewen A, Bordigoni P, Witz F, et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12:197-202.
110. Campolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1996; 17:589-93.
111. Roberts WD, Weinberg KI, Kohn DB, et al. Granulocyte recovery in pediatric marrow transplant recipients treated with ganciclovir for cytomegalovirus infection. Am J Pediatr Hematol Oncol 1993; 15:320-3.
112. Gonczol E, Ianacone J, Ho W, Starr S, Meignier B, Plotkin S. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelopes induces humoral and cellular immune-responses in human volunteers. Vaccine 1990; 8:130-6.
113. McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific CTL. J Med Virol 1994; 43:103-10.